Cancer Vaccines: Powerful Tool in Cancer Immunotherapy of breast cancer

Dendritic Cell Activity

Dendritic Cell Activity



Cancer vaccine is widely considered as a powerful tool in immunotherapy. In this trial, a versatile cancer cell membrane (CCM) coated calcium carbonate (CC) nanoparticles (MC) that capable of generating in situ tumor-associated antigens (TAAs) for DC vaccination is examined in detail. Overall, this novel DDS integrating chemotherapy and PDT with the combination of immunotherapy might offer further inspirations for the scientific researchers in cancer therapy.


Dendritic cells are key players in the immune system. They play a crucial role in antigen processing and presentation, which is an important part of dendritic cell therapy for cancer treatment.


Researchers have made dendrites into targets for vaccine development to turn dendritic cells into powerful cancer killers that can eradicate tumors while sparing normal tissue. DCs have gained much attention as therapeutic vaccine candidates due to their ability to activate both CD4+ T helper cells and CD8+ cytotoxic T lymphocytes against tumor antigens, leading to increased immunity against cancers.



Dendritic cell (DC) therapy is a promising immunotherapy approach for cancer treatment. In dendritic cells, the antigen processing and presentation natures have been shown to be effective in activating dendritic cell-mediated immune responses against tumors. DC vaccine has been tested clinically as an anticancer agent for breast cancer patients with some success.



Cancer vaccine is widely considered as a powerful tool in immunotherapy. In particular, the effective antigen processing and presentation natures of dendritic cell (DC) have made it a promising target for the development of therapeutic vaccine for breast cancer treatment.

Article Reference link: click here

Scientific article publishing date : 25/2/2020

Immucura identifier : BSC21_014EN